Table 3. Baseline characteristics of participants lost to follow-up after 5 years and participants deceased after 5 years, compared with participants available for analyses after 5 years, per patient group (without imputed missing values)
1: MPCs LTFU after 5 years (n = 261)2: MPCs deceased after 5 years (n = 91)3: MPCs available for analysis after 5 years (n = 271)P value 1 versus 3P value 2 versus 34: OPCs LTFU after 5 years (n = 160)5: OPCs deceased after 5 years (n = 106)6: OPCs available for analysis after 5 years (n = 104)P value 4 versus 6P value 5 versus 67: OPs LTFU after 5 years (n = 195)8: OPs deceased after 5 years (n = 66)9: OPs available to analysis after 5 years (n = 166)P value 7 versus 9P value 8 versus 9
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Sex (women) 182 (69.7)38 (41.8)209 (77.1)0.05<0.01a 111 (69.4)51 (48.1)80 (76.9)0.180<0.01a 121 (62.1)35 (53)104 (62.7)0.9070.177
Mean age, years (SD) 60 (5.5)62 (5.5)60 (5.3)77 (4.8)76 (5.4)74 (4.6)78 (5.4)82 (5.8)77 (5.1)
Marital status 0.3290.1830.0450.5760.2320.389
Married or living together202 (78)69 (75.8)212 (78.5)78 (49.4)67 (63.8)65 (62.5)127 (65.8)36 (54.5)101 (60.6)
Unmarried or divorced or widowed55 (21.2)21 (23.1)57 (21.1)78 (49.4)38 (36.2)37 (35.6)66 (34.2)30 (45.5)62 (37.3)
Other2 (0.8)1 (1.1)1 (0.4)2 (1.3)2 (1.9)3 (1.8)
Age leaving school 0.1860.208<0.01a 0.229<0.01a <0.01a
≤14 years32 (12.7)13 (14.6)25 (9.4)53 (34.2)28 (27.2)24 (24)63 (33.3)29 (43.9)55 (23)
15–18 years128 (50.8)45 (50.6)124 (46.8)79 (51)53 (51.5)44 (44)91 (48.1)29 (43.9)108 (44)
≥19 years92 (36.5)31 (34.8)116 (43.8)23 (14.8)22 (21.4)32 (32)35 (18.5)8 (12.1)81 (33)
Type of tumour <0.01a <0.01a <0.01a <0.01a
Breast146 (55.9)13 (14.3)186 (68.6)85 (53.1)34 (32.1)78 (75)
Gastrointestinal78 (29.9)31 (34.1)60 (22.1)56 (35)38 (35.8)20 (19.2)
Lung18 (6.9)42 (46.2)2 (0.7)11 (6.9)27 (25.5)
Prostate19 (7.3)5 (5.5)23 (8.5)8 (5)7 (6.6)6 (5.8)
Distress (yes) 84 (35.3)33 (37.9)95 (37.1)0.6750.89140 (32.8)25 (28.1) 31 (39.7)0.3160.11146 (24.7)15 (23.1)26 (16)0.0460.213
Fatigue (yes) 49 (19.1)23 (25.3)33 (12.2)0.030<0.01a 20 (15.2)27 (27.8) 11 (13.9)0.8070.02618 (9.2)9 (13.6)8 (4.8)0.1060.020
Functional status (dependent) 122 (48.8)50 (55.6)121 (45.8)0.5000.11193 (58.9)68 (66)66 (63.5)0.4560.700105 (54.1)45 (69.2)79 (47.9)0.238<0.01a
Cancer stage 0.204<0.01a <0.01a <0.01a
I & II167 (73.9)13 (24.5)187 (78.9)92 (74.2)29 (42)79 (89.8)
III & IV59 (26.1)40 (75.5)50 (21.1)32 (25.8)40 (58)9 (10.2)
Treatment type 0.440<0.01a 0.406<0.01a
Surgery only43 (19.5)5 (14.7)44 (17.2)17 (14.2)3 (5.4)14 (14.9)
Surgery and RT or HT or both71 (32.1)22 (64.7)73 (28.5)28 523.3)24 (42.9)15 (16)
Surgery and CT with or without any combination of RT or HT or IT107 (48.4)7 (20.6)139 (54.3)75 (62.5)29 (51.8)65 (69.1)
  • CI = confidence interval. CT = chemotherapy. HT = hormone therapy. IT = immunotherapy. OR = odds ratio. LTFU = lost to follow-up. MPCs = middle-aged patients with cancer. OPCs = older patients with cancer. OPs = older patients without cancer. RT = radiotherapy. SD = standard deviation.

  • aStatistically significant (P<0.01).